Bevacizumab zirconium Zr-89

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bevacizumab zirconium Zr-89
DrugBank Accession Number
DB14907
Background

Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).

Type
Biotech
Groups
Investigational
Synonyms
  • 89ZR-BEVACIZUMAB

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Bevacizumab zirconium Zr-89.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab zirconium Zr-89.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Bevacizumab zirconium Zr-89.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab zirconium Zr-89.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Bevacizumab zirconium Zr-89.
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
B552L536ZL
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
0CompletedDiagnosticInflammatory Breast Carcinoma1somestatusstop reasonjust information to hide
Not AvailableCompletedNot AvailableNeuroendocrine Tumors1somestatusstop reasonjust information to hide
Not AvailableRecruitingNot AvailableNeurofibromatosis, type 2 (acoustic neurofibromatosis)1somestatusstop reasonjust information to hide
Not AvailableUnknown StatusDiagnosticMultiple Myeloma (MM)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 14:33 / Updated at June 12, 2020 16:53